|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: FBXW9 |
Gene summary for FBXW9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | FBXW9 | Gene ID | 84261 |
| Gene name | F-box and WD repeat domain containing 9 | |
| Gene Alias | Fbw9 | |
| Cytomap | 19p13.13 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | Q5XUX1 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 84261 | FBXW9 | LZE2T | Human | Esophagus | ESCC | 8.08e-04 | 3.44e-01 | 0.082 |
| 84261 | FBXW9 | LZE7T | Human | Esophagus | ESCC | 7.63e-04 | 1.58e-01 | 0.0667 |
| 84261 | FBXW9 | LZE24T | Human | Esophagus | ESCC | 3.89e-05 | 2.34e-01 | 0.0596 |
| 84261 | FBXW9 | P1T-E | Human | Esophagus | ESCC | 3.37e-05 | 1.85e-01 | 0.0875 |
| 84261 | FBXW9 | P2T-E | Human | Esophagus | ESCC | 1.76e-12 | 1.65e-01 | 0.1177 |
| 84261 | FBXW9 | P4T-E | Human | Esophagus | ESCC | 1.24e-09 | 1.51e-01 | 0.1323 |
| 84261 | FBXW9 | P5T-E | Human | Esophagus | ESCC | 7.31e-03 | 7.80e-02 | 0.1327 |
| 84261 | FBXW9 | P8T-E | Human | Esophagus | ESCC | 6.93e-04 | 1.25e-01 | 0.0889 |
| 84261 | FBXW9 | P9T-E | Human | Esophagus | ESCC | 1.33e-03 | 1.17e-01 | 0.1131 |
| 84261 | FBXW9 | P10T-E | Human | Esophagus | ESCC | 9.54e-12 | 2.45e-01 | 0.116 |
| 84261 | FBXW9 | P11T-E | Human | Esophagus | ESCC | 2.29e-12 | 3.70e-01 | 0.1426 |
| 84261 | FBXW9 | P12T-E | Human | Esophagus | ESCC | 5.91e-09 | 1.65e-01 | 0.1122 |
| 84261 | FBXW9 | P15T-E | Human | Esophagus | ESCC | 3.25e-09 | 1.33e-01 | 0.1149 |
| 84261 | FBXW9 | P16T-E | Human | Esophagus | ESCC | 1.82e-05 | 1.88e-01 | 0.1153 |
| 84261 | FBXW9 | P17T-E | Human | Esophagus | ESCC | 6.22e-03 | 1.55e-01 | 0.1278 |
| 84261 | FBXW9 | P20T-E | Human | Esophagus | ESCC | 1.01e-10 | 2.66e-01 | 0.1124 |
| 84261 | FBXW9 | P21T-E | Human | Esophagus | ESCC | 5.81e-13 | 3.52e-01 | 0.1617 |
| 84261 | FBXW9 | P22T-E | Human | Esophagus | ESCC | 3.50e-09 | 2.11e-01 | 0.1236 |
| 84261 | FBXW9 | P23T-E | Human | Esophagus | ESCC | 2.23e-18 | 4.13e-01 | 0.108 |
| 84261 | FBXW9 | P24T-E | Human | Esophagus | ESCC | 8.08e-08 | 1.89e-01 | 0.1287 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| FBXW9 | SNV | Missense_Mutation | rs753182889 | c.805N>A | p.Val269Met | p.V269M | Q5XUX1 | protein_coding | deleterious(0) | probably_damaging(0.964) | TCGA-BH-A0BS-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | adriamycin | CR |
| FBXW9 | SNV | Missense_Mutation | novel | c.1196T>C | p.Val399Ala | p.V399A | Q5XUX1 | protein_coding | tolerated(0.77) | benign(0.001) | TCGA-5M-AAT6-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Unknown | Unknown | PD |
| FBXW9 | SNV | Missense_Mutation | novel | c.267G>T | p.Glu89Asp | p.E89D | Q5XUX1 | protein_coding | deleterious(0.02) | benign(0.217) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
| FBXW9 | SNV | Missense_Mutation | rs199501539 | c.701N>T | p.Ala234Val | p.A234V | Q5XUX1 | protein_coding | deleterious(0.01) | probably_damaging(0.946) | TCGA-WS-AB45-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FBXW9 | SNV | Missense_Mutation | rs745933672 | c.874G>A | p.Asp292Asn | p.D292N | Q5XUX1 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
| FBXW9 | SNV | Missense_Mutation | novel | c.760N>A | p.Ala254Thr | p.A254T | Q5XUX1 | protein_coding | tolerated(0.45) | benign(0.167) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| FBXW9 | SNV | Missense_Mutation | novel | c.923N>T | p.Arg308Ile | p.R308I | Q5XUX1 | protein_coding | deleterious(0.01) | benign(0.063) | TCGA-AP-A051-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| FBXW9 | SNV | Missense_Mutation | c.883N>T | p.Ala295Ser | p.A295S | Q5XUX1 | protein_coding | deleterious(0.03) | benign(0.367) | TCGA-AP-A0LG-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| FBXW9 | SNV | Missense_Mutation | rs760934757 | c.1024C>T | p.Arg342Cys | p.R342C | Q5XUX1 | protein_coding | deleterious(0.02) | possibly_damaging(0.804) | TCGA-AP-A0LM-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | cisplatin | SD |
| FBXW9 | SNV | Missense_Mutation | c.649T>G | p.Leu217Val | p.L217V | Q5XUX1 | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-AP-A1DK-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |